This is a StreetInsider.com Premium Only Page

(ZYME) – Business Wire

Jun 7, 2023 08:00 AM At BIO 2023, Canada Showcases Multiple Strengths as a Biopharma Powerhouse

Jun 5, 2023 08:00 AM At BIO 2023, Canada Showcases Multiple Strengths as a Biopharma Powerhouse

Apr 17, 2023 08:30 AM Zymeworks To Host First Quarter 2023 Results Conference Call

Apr 10, 2023 08:30 AM Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

Apr 3, 2023 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conferences

Mar 14, 2023 04:30 PM Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting

Mar 7, 2023 04:05 PM Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 28, 2023 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conferences

Feb 21, 2023 08:30 AM Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call

Jan 25, 2023 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conferences

Jan 4, 2023 04:15 PM Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

Dec 21, 2022 07:30 AM Zymeworks Announces Participation in Upcoming Investor Conference

Dec 19, 2022 07:00 AM Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

Dec 14, 2022 04:15 PM Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Dec 9, 2022 08:00 AM New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS

Dec 5, 2022 08:30 AM Zymeworks to Transfer Stock Listing to Nasdaq

Nov 29, 2022 08:30 AM Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals

Nov 22, 2022 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conference

Nov 21, 2022 09:00 AM Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)

Nov 8, 2022 04:22 PM Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Oct 20, 2022 08:30 AM Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms

Oct 19, 2022 06:07 AM Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab

Oct 18, 2022 08:30 AM Zymeworks to Host Third Quarter Results Conference Call

Oct 13, 2022 07:00 AM Zymeworks Completes Plan to Become Delaware Corporation

Oct 7, 2022 04:15 PM Zymeworks Announces Results of Special Meeting

Oct 4, 2022 08:30 AM Zymeworks Reminds Shareholders to Vote FOR its Redomicile

Oct 3, 2022 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day

Sep 26, 2022 04:15 PM Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile

Sep 16, 2022 08:30 AM Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile

Sep 12, 2022 04:15 PM Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress

Sep 8, 2022 04:15 PM Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware

Sep 4, 2022 06:05 PM Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

Aug 4, 2022 04:15 PM Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Aug 1, 2022 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conferences

Jul 25, 2022 08:30 AM Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris

Jul 22, 2022 08:30 AM Zymeworks Reports Inducement Grant to New Chief Scientific Officer

Jul 21, 2022 08:30 AM Zymeworks to Host Second Quarter Results Conference Call

Jul 15, 2022 08:00 AM Zymeworks Announces Plan to Become a Delaware Corporation

Jun 27, 2022 08:30 AM Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer

Jun 10, 2022 09:15 AM Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company

May 27, 2022 05:30 AM Zymeworks Announces Participation in Upcoming Investor Conference

May 26, 2022 05:00 PM Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022

May 20, 2022 09:15 AM Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal

May 4, 2022 04:15 PM Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 2, 2022 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conferences

Apr 28, 2022 09:00 PM Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons

Apr 28, 2022 08:30 AM Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer

Apr 27, 2022 04:15 PM Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 19, 2022 04:15 PM Zymeworks to Host First Quarter 2022 Results Conference Call

Apr 1, 2022 08:30 AM Zymeworks Announces Participation in Upcoming Investor Conferences